Bioasis grants 225,000 RSUs, 80-cent options

2017-04-24 18:16 ET - News Release

Mr. Rob Hutchison reports

BIOASIS ANNOUNCES GRANT OF STOCK OPTIONS AND RESTRICTED STOCK UNITS

Pursuant to the terms of a stock option plan and a restricted stock unit plan, Bioasis Technologies Inc. has granted a total of 2,377,478 stock options and 225,000 restricted share units to its officers, employees, consultants and members of the board of directors. The stock options are exercisable at a price of $0.80 per share for a period of five years from the date of grant.

Pursuant to the investor relations agreement between the Company and 551943 Alberta Ltd. (operating as Colwell Capital Corp) ("Colwell"), announced on April 24, 2017, the Company has granted a total of 175,000 stock options to Colwell. These stock options are exercisable at a price of $0.80 per share for a period of five years from the date of grant. The IR options will vest quarterly over twelve months, with 43,750 stock options vesting on July 24, 2017, 43,750 vesting on October 24, 2017, 43,750 vesting on January 24, 2018 and 43,750 vesting on April 24, 2018.

The stock options and RSUs follow the guidelines as set out in the Company's Option Plan and RSU Plan and as set by the TSX Venture Policies. The RSU grants are subject to the approval of the TSX Venture Exchange.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The Company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. For more information about the company please visit www.bioasis.ca.

We seek Safe Harbor.